

2022 Healthcare and Life Sciences Investment Outlook
Our 2022 Healthcare and Life Sciences Investment Outlook offers a look into industry innovations with the greatest investor interest.
Video transcript
M&A in 2021 was an absolute crush, crush to market in many different situations. When we look at life sciences as a whole, we had an average of about 460 deals on a quarterly basis, which was up from 2020, about 405. Healthcare had a huge spike in deals with respect to home care, hospice, personal care, big spike on healthcare IT. That was no surprise, but a lot of traction there. So we're very excited for our M&A in 2022 and look forward to having more of a deeper dive within healthcare and life sciences.
Related content